GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Everest Medicines Ltd (HKSE:01952) » Definitions » Other Long Term Assets

Everest Medicines (HKSE:01952) Other Long Term Assets : HK$40.8 Mil (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Everest Medicines Other Long Term Assets?

Everest Medicines's other long-term assets for the quarter that ended in Dec. 2024 was HK$40.8 Mil.

Everest Medicines's quarterly other long-term assets declined from Dec. 2023 (HK$62.2 Mil) to Jun. 2024 (HK$57.0 Mil) but then stayed the same from Jun. 2024 (HK$57.0 Mil) to Dec. 2024 (HK$40.8 Mil).

Everest Medicines's annual other long-term assets declined from Dec. 2022 (HK$199.1 Mil) to Dec. 2023 (HK$62.2 Mil) and declined from Dec. 2023 (HK$62.2 Mil) to Dec. 2024 (HK$40.8 Mil).


Everest Medicines Other Long Term Assets Historical Data

The historical data trend for Everest Medicines's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Everest Medicines Other Long Term Assets Chart

Everest Medicines Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Long Term Assets
Get a 7-Day Free Trial 1,010.87 1,045.63 199.07 62.17 40.80

Everest Medicines Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Other Long Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 199.07 84.20 62.17 57.02 40.80

Everest Medicines Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.


Everest Medicines Business Description

Traded in Other Exchanges
Address
1168 West Nanjing Road, 16th Floor, CITIC Pacific Plaza, Jing’an District, Shanghai, CHN, 200041
Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes; Nefecon (TarpeyoTM), EVER001 (previously known as XNW1011), PTX-COVID19-B, Eravacycline (Xerava), EVER206 (also known as SPR206), and others. Geographically operates in Mainland China.
Executives
Fu Wei 2307 Founder of a discretionary trust who can infl
Nova Aqua Limited 2201 Interest of corporation controlled by you
C-bridge Capital Gp Iv, Ltd. 2201 Interest of corporation controlled by you
C-bridge Healthcare Fund Gp Iv, L.p. 2201 Interest of corporation controlled by you
C-bridge Healthcare Fund Iv, L.p. 2201 Interest of corporation controlled by you
Tf Capital Iv Ltd. 2201 Interest of corporation controlled by you
C-bridge Capital Gp, Ltd. 2501 Other
C-bridge Healthcare Fund Gp Ii, L.p. 2501 Other
C-bridge Healthcare Fund Ii, L.p. 2501 Other
C-bridge Investment Everest Limited 2501 Other
Tf Capital Ii Ltd. 2501 Other
Everest Management Holding Co., Ltd. 2101 Beneficial owner
Fu Wei 2307 Founder of a discretionary trust who can infl
C-bridge Joint Value Creation Limited 2201 Interest of corporation controlled by you
Kolchinsky Anna Inge Leonore Haas 2202 Interest of your spouse

Everest Medicines Headlines

No Headlines